MHRA's Q2 Results and Forecast report: what UK regulatory teams should check

What happened

On 12 November 2026 the MHRA added Quarter 2 to its 2026/27 Results and Forecast reporting. The UK regulator posted a second-quarter performance report and an accompanying letter on GOV.UK. The release extends a quarterly transparency series that began in August.

The records available to us do not include the report's contents. We cannot say how the MHRA performed against its targets, what it forecasts for the rest of the year, or what the letter says. This article therefore looks at what the publication means as a mechanism, and what teams should look for when they read the full documents.

Why a quarterly rhythm matters

A second consecutive release turns a one-off disclosure into a series. For regulatory affairs teams, that makes quarter-on-quarter comparison possible. Trends in the MHRA's own reporting are more useful for planning than any single snapshot.

The title also suggests that each report pairs results with a forecast. If so, the forecast element is what deserves the closest reading. Teams building UK submission calendars, whether for new marketing authorisations, variations or device-related interactions, need to know whether the regulator's own outlook has moved since August. Whether it has moved is not stated in our records and should be checked against the source documents.

The contrast: how timelines are signalled elsewhere

Other regulators give sponsors timeline signals at the level of individual products. The same day's records show this in the US. The FDA accepted Intellia's biologics licence application for lonvoguran ziclumeran, a one-time in vivo gene-editing therapy for hereditary angioedema, with priority review and a PDUFA goal date of 10 March 2027. No advisory committee is currently planned. A PDUFA date is the date by which the FDA aims to complete its review. It gives a sponsor, and its partners and payers, a fixed point to plan around.

A system-level report like the MHRA's tells you about the regulator's overall throughput rather than one file. The two are complementary. A product-level date answers when one decision is due. A performance report helps you judge how much confidence to place in the timelines you are building for the UK.

Sponsor-side disclosures show that timing risk often sits outside the regulator. Candel Therapeutics now expects to file its aglatimagene besadenovec application in mid-2027, citing the time needed to refine an assay with the FDA. The company reports cash of $203.1 million. The delay comes from preparing the submission, not from review speed. Regulator performance data cannot capture that kind of slippage, so UK teams still need their own readiness tracking.

Who is affected and where the knock-on effects sit

Marketing authorisation holders and applicants with UK filings planned in the coming months are the most obvious audience. Medical device manufacturers should also pay attention. The InspireMD records show how device timelines run in the US. The FDA approved a PMA supplement for the CGuard Prime 80 cm system in transcarotid artery revascularisation for high-surgical-risk patients, based on the 50-patient CGUARDIANS II trial. The company says another PMA supplement is planned for December and that a recalled delivery system is due back in 2027. Sequencing like this is easier to manage when regulators publish dependable operating data.

Post-market obligations are the other pressure point. Health Canada listed Type II recalls on the same day. Siemens is issuing hotfix XB20A-HF02 for seven MAGNETOM Flow.Elite scanners and XB10B-HF02 for two more systems. Both address coil detection, logging, start-up stability and patient table reliability. GE HealthCare's Centricity Universal Viewer was recalled over a vulnerability that could allow unauthorised access to patient data when launched from third-party applications. Health Canada also warned about unauthorised peptides after Sphingomonas bacteria were found in an injectable product seized in Ottawa. It lists ten unauthorised injectable and oral products.

None of these items concerns the MHRA, and we draw no conclusion about UK activity from them. They do show that regulators handle premarket review and post-market vigilance in parallel. Any regulator's performance reporting is best read as one signal about the whole system, not just the approvals queue.

What to watch

First, read the Q2 report and letter against the August release, and note any changes in stated targets, forecasts or caveats. Second, watch whether the series continues each quarter, since regularity is what makes it usable for planning. Third, check whether the reporting covers the activities you depend on, such as applications, variations or device-related work, or only part of the regulator's workload.

What is not yet known from our records is the substance of the figures. Any internal forecast change driven by this report should wait until someone on your team has read the source.